-Member Login

Forgot your USERNAME OR PASSWORD?

Job Postings

Let's Stay Connected

Find us on the popular social networks

Facebook Twitter LinkedIn Flicker

Journal Highlights

DMD Highlight: Application of Static Modeling ­­in the Prediction of In Vivo Drug–Drug Interactions between Rivaroxaban and Antiarrhythmic Agents

Posted on 2/17/2017 1:50:25 PM

DMD Highlights March 2017 Cheong et al
 

Rivaroxaban, a direct Factor Xa inhibitor, is indicated for stroke prevention in nonvalvular atrial fibrillation (AF) and amiodarone and dronedarone are antiarrhythmic agents employed in AF management. In vitro assays using rivaroxaban as the probe substrate were used to study inhibition of CYP3A4 and 2J2 by amiodarone, dronedarone and their metabolites. The inhibition parameters were fitted into a mechanistic static model, which predicted a 37% and 31% increase in rivaroxaban exposure due to the inhibition of hepatic and gut metabolism by amiodarone and dronedarone, respectively.

See the article by Cheong et al. at Drug Metabolism and Disposition March 2017, 45 (3) 260-268; DOI: https://doi.org/10.1124/dmd.116.073890 

Comments (0)


Leave a comment


Blog comments are moderated and will be posted once approved.

Name


Comment:


Enter the code shown below:

Recent Posts

Archive

.

Hot Links 

EB2017 

Join ASPET 

What is Pharmacology? Video 

PharmTalk Blog